Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
received:
15
05
2023
accepted:
20
07
2023
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Nintedanib reduces the decline in forced vital capacity and extends the time to the first acute exacerbation of interstitial lung disease (AE-ILD). However, the effect of additional nintedanib administration after AE-ILD onset is unknown. This study aimed to investigate the efficacy and safety of nintedanib administration after AE-ILD development. We retrospectively collected the data of 33 patients who developed AE-ILD between April 2014 and January 2022. Eleven patients who received nintedanib after AE-ILD development and the remaining who did not were classified into the N and No-N groups, respectively. The survival time in the N group tended to be longer than that in the No-N group. The generalized Wilcoxson test revealed that the cumulative mortality at 90 days from AE-ILD onset was significantly lower in the N group. The time to subsequent AE-ILD development was significantly longer in the N group than that in the No-N group. The incidence of adverse gastrointestinal effects and liver dysfunction in the N group was 9-18%. Treatment without nintedanib after AE-ILD development and the ratio of arterial oxygen partial pressure to fractional inspired oxygen were significant independent prognostic factors in the multivariate analysis. Thus, nintedanib administration may be a treatment option for AE-ILD.
Identifiants
pubmed: 37532874
doi: 10.1038/s41598-023-39101-w
pii: 10.1038/s41598-023-39101-w
pmc: PMC10397323
doi:
Substances chimiques
nintedanib
G6HRD2P839
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12528Informations de copyright
© 2023. The Author(s).
Références
Respir Res. 2014 Sep 01;15:109
pubmed: 25176016
Br J Cancer. 2007 Jun 18;96(12):1788-95
pubmed: 17519900
Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66
pubmed: 25245821
Ann Oncol. 2011 Jun;22(6):1374-1381
pubmed: 21212157
Respirology. 2017 May;22(4):750-757
pubmed: 27997064
Am J Respir Crit Care Med. 2020 May 1;201(9):1110-1119
pubmed: 31917621
Am J Respir Crit Care Med. 2008 Aug 15;178(4):372-8
pubmed: 18451320
Mol Cancer Ther. 2010 Oct;9(10):2825-33
pubmed: 20688946
Cancer Res. 2008 Jun 15;68(12):4774-82
pubmed: 18559524
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Core Evid. 2015 Aug 27;10:89-98
pubmed: 26346347
Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69
pubmed: 32706311
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7
pubmed: 15665326
Eur Respir Rev. 2018 Dec 21;27(150):
pubmed: 30578331
Chest. 1993 Jun;103(6):1808-12
pubmed: 8404104
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
Lancet Respir Med. 2022 Jan;10(1):26-34
pubmed: 34506761
Lancet Oncol. 2019 May;20(5):625-635
pubmed: 30975627
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Am J Respir Crit Care Med. 2014 Oct 1;190(7):773-9
pubmed: 25162152
Eur Respir J. 2017 May 19;49(5):
pubmed: 28526798
Curr Oncol Rep. 2012 Aug;14(4):295-306
pubmed: 22532265
Mol Cell. 1999 Dec;4(6):915-24
pubmed: 10635317
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Respir Investig. 2018 Jul;56(4):268-291
pubmed: 29980444
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Respirology. 2019 Aug;24(8):792-798
pubmed: 30803100
Respir Med Case Rep. 2019 Feb 28;26:317-320
pubmed: 30931251
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Respirology. 2020 May;25(5):525-534
pubmed: 31426125
Crit Care. 2018 Mar 23;22(1):80
pubmed: 29566734
Respirol Case Rep. 2017 Jan 12;5(2):e00215
pubmed: 28096998
Respir Investig. 2019 Jul;57(4):300-311
pubmed: 30853366
Thorax. 2006 Jul;61(7):621-6
pubmed: 16807391
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Sci Rep. 2019 Aug 19;9(1):12062
pubmed: 31427707
Respir Med Case Rep. 2020 Feb 07;29:101022
pubmed: 32071858